U.S. SECURITIES AND
                               EXCHANGE COMMISSION
                                WASHINGTON, D.C.


                                  FORM 12B-25/A
                                  Amendment #1



                           NOTIFICATION OF LATE FILING


                                                                 SEC File Number
                                                                    33-26787-D

                                                                  CUSIP Number
                                                                   989865 10 0


             (Check One) [X] Form 10-KSB [ ] Form 20-F [ ] Form 11-K
                          [ ] Form 10-Q [ ] Form N-SAR

                       For Period Ended December 31, 2005
                                        -----------------

                  [  ]  Transition Report on Form 10-K
                  [  ]  Transition Report on Form 20-F
                  [  ]  Transition Report on Form 11-K
                  [  ]  Transition Report on Form 10-Q
                  [  ]  Transition Report on Form N-SAR

                   For the Transition Period Ended ___________

 [Read Instruction (on back page) Before Preparing Form. Please Print or Type ]
      Nothing in this form shall be construed to imply that the Commission
                 has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates: Not Applicable



PART I -- REGISTRANT INFORMATION

Zynex Medical Holdings, Inc
- --------------------------------------------------------------------------------
Full Name of Registrant

Fox River Holdings Inc.
- --------------------------------------------------------------------------------
Former Name if Applicable

8100 Southpark Way,  Suite A-9
- --------------------------------------------------------------------------------
Addresses of Principal Executive Office

Littleton, CO  80120
- --------------------------------------------------------------------------------
City, State and Zip Code

PART II -- RULES 12B-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate) [X]

               (a)  The reasons described in reasonable detail in Part III of
- ----                this form could not be eliminated without unreasonable
                    effort or expense;
 X
- ----           (b)  The subject annual report, semi-annual report, transition
                    report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or
                    portion thereof, will be filed on or before the fifteenth
                    calendar day following the prescribed due date; or the
                    subject quarterly report of transition report on Form 10-Q,
                    or portion thereof will be filed on or before the fifth
                    calendar day following the prescribed due date; and

- ----           (c)  The accountant's statement or other exhibit required by Rule
                    12b-25(c) has been attached if applicable.

                                        2




PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR or the transition report or portion thereof, could not be filed in the
prescribed period.

     The Company's December 31, 2005 year-end financial statements are still
being prepared. Factors contributing to the delay, include among others the
Company's change in accountants in December of 2005 and the Company's limited
staff. The Company will be unable to complete the 2005 annual report on Form
10-KSB by the initial filing date of the Form 10-KSB without unreasonable effort
or expense.


PART IV -- OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this
     notification:

             Thomas Sandgaard                  (800)                495-6670
         ---------------------------        ------------      ------------------
                  (Name)                    Area Code         Telephone Number

(2)  Have all other periodic reports required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter period that the
     registrant was required to file such report(s) been filed? If the answer is
     no, identify report(s).      Yes      [X]       No       [  ]

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding period for the last fiscal year will be reflected by the
     earnings statements to be included in the subject report of portion
     thereof?                     Yes      [X]       No       [  ]

     If so, attach an explanation of the anticipated change, both narratively
and quantatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.

     Items, such as increased revenues and decreased expenses, will result in
changes in the operating results of the year ended December 31, 2005 compared to
the year ended December 31, 2004. However, the Company has not completed its
financial statements for the 2005 fiscal year. Therefore, the Company is not in
a position at this time to provide any reasonable estimate of any anticipated
significant changes in the results of operations for the year ended December 31,
2005 compared to the year ended December 31, 2004.


                          Zynex Medical Holdings, Inc.
                   ------------------------------------------
                  (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.


Date:    March 28, 2006                        By:   /s/ Thomas Sandgaard
      ------------------                             ---------------------------
                                                     Thomas Sandgaard
                                                     Chief Executive Officer and
                                                     Chief Financial Officer

                                        3